US approves first drug treatment for sleep apnea

"This is a major step forward for patients with obstructive sleep apnea," US Food and Drugs Administration official Sally Seymour said in a statement announcing approval of Zepbound to treat moderate to severe sleep apnea in obese patients. Zepbound, from drugmaker Eli Lilly, is already approved for people who are obese or overweight and have a related health condition, such as type 2 diabetes, high cholesterol or high blood pressure. "Zepbound works by activating receptors of hormones secreted...